BIONANO GENOMICS DL-,0001 Forum: Community User: Shruikan

20$ 😬😬😬 träumchen

Seit Monaten jagt ein Jahrestief das nächste bald sind wir garantiert wieder bei 1 Dollar schade aber ändern können wir das auch nicht mehr und @Per 20 Dollar werden wir hier wahrscheinlich niemals mehr sehen auch wenn du daran festhältst es wäre uns allen zu wünschen aber ich denke das hier Hopfen und Malz unwiderruflich verloren ist!

1000 Dank.

https://www.boersennews.de/community/diskussion/bngo-news-und-infos/51059/

@Metrolpolis! Ich schnapp mir mal deine News und pack sie in unser NEWS-Forum -->

https://www.youtube.com/watch?v=JGuWb_81als

Oh man!!!

@john,klar kannst du nicht einschlafen da unsere Unterstützung richtig bröckelt. Es knarrt an allen Ecken und Enden.

Ich kann nicht einschlafen. Ohje!!!!

Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data today announced the publication of a study that evaluated the performance and clinical utility of combining OGM and a 523-gene next-generation sequencing (NGS) panel for comprehensive evaluation of myeloid tumors and compared it to standard cytogenetic methods (karyotyping and fluorescence in situ hybridization (FISH) and a 54-gene NGS panel. This study reported superior performance as compared to standard methods and marks two major developments in the ongoing evaluation of combined OGM and NGS workflows. This study is the first published example where the combination of workflows was applied in the context of myeloid cancers, and demonstrated higher sensitivity, resolution, accuracy and ability to reveal cryptic and clinically relevant novel variants in myeloid cancers as compared to standard methods. This is also the first study to publish results using the simultaneous visualization and interpretation of sequence and copy number variants (CNVs) in the BioDiscovery NxClinical software v6.1 from OGM and NGS data. “This research demonstrated that the combination of OGM and a 523-gene NGS panel is superior to standard methods and cost effective for comprehensive genomic profiling of myeloid cancers. When compared to whole-genome sequencing approaches that others have suggested, I believe it has better detection performance at a lower cost,” commented Dr. Ravindra Kolhe, Associate Dean for Translational Research at Medical College of Georgia and Director of the Georgia Esoteric and Molecular Laboratory at Augusta University. “With new tools to simultaneously visualize sequence variants and structural variants, we are well-positioned to move this approach into routine use, which we expect will deepen our understanding of hematological malignancies.” The research, led by Dr. Kolhe’s team at the Medical College of Georgia/Augusta University, evaluated the use of OGM and a 523-gene NGS panel for genomic profiling of 15 myeloid tumors and compared results to karyotyping, FISH, and a 54-gene NGS panel. Results demonstrated 100% analytical concordance of OGM and the 523-gene NGS panel for variants found with traditional methods. In addition, OGM better characterized structural variants (SVs) previously reported by karyotyping in five cases and identified additional translocations and 11 CNVs. “We believe this publication demonstrates the advantages of performing OGM side-by-side with NGS, for a combined workflow that can provide a more comprehensive, accurate detection of genetic variants at a cost and complexity that is practical for laboratories,” commented Erik Holmlin, PhD, President and Chief Executive Officer of Bionano. “With NxClinical software that allows for combined visualization of sequence and structural variants, we believe we have provided a tool that can make a combined OGM and NGS approach simple, scalable and superior to traditional methods.”

BIONANO GENOMICS ANNOUNCES PUBLICATION OF THE FIRST STUDY TO COMBINE OGM AND NGS TO EVALUATE MYELOID CANCERS - Whole genome analysis by OGM together with analysis using a 523-gene NGS panel can perform better and cost less than analysis with karyotyping, FISH, and a 54-gene NGS panel - First study to publish results using NxClinical software for simultaneous visualization and interpretation of sequence and copy number variants from NGS and OGM data https://ir.bionanogenomics.com/news-releases/news-release-details/bionano-genomics-announces-publication-first-study-combine-ogm

Bin etwas erschüttert , das wir überhaupt so tief runter sind . Nun gibt es eben neue Chancen . Schauen wir mal ;) Lg

Ich arbeite die Tage mal was aus welche Möglichkeiten wir hätten . Fakt ist 1,5$ oder 3,5$ stehen schonmal im Raum ;)

🥒🥒🥒 ... mach ich! ... und ab auf die Couch!

Moin John , auf jeden Fall geht heute was, entweder up oder down . Hm, warte mal was meine Kugel sagt…. Du sollst sofort auf die Couch und heija machen 💪🏿🥒🥒🥒.